Resmetirom for Metabolic-Associated Liver Disease
Resmetirom should be considered for adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2), as it is the first FDA-approved MASH-targeted therapy demonstrating histological efficacy on both steatohepatitis and fibrosis with acceptable safety. 1
Who Should Receive Resmetirom
Primary indication:
- Non-cirrhotic MASH patients with fibrosis stage F2 or F3 (significant to advanced fibrosis)
- This represents the strongest recommendation from 2024 EASL-EASD-EASO guidelines 1
Alternative candidates (if locally approved):
- Patients with advanced fibrosis documented by liver biopsy
- At-risk steatohepatitis with significant fibrosis confirmed by validated non-invasive panels
- High risk of adverse liver-related outcomes based on elastography or biomarker thresholds (e.g., LSM-VCTE 10-20 kPa) 1, 2
Critical Exclusions
Do NOT use resmetirom in:
- Cirrhotic patients - No MASH-targeted pharmacotherapy is currently recommended for cirrhosis 1
- Decompensated cirrhosis (Child-Pugh B or C) - Avoid due to increased drug exposure and adverse reaction risk 3
- Active liver disease from other causes
- Untreated thyroid disorders 4
Practical Implementation
Diagnosis and staging without mandatory biopsy:
- Use FIB-4 score as initial screening
- Follow with vibration-controlled transient elastography (VCTE) or MR elastography
- LSM-VCTE 10-20 kPa or MRE 3.1-4.4 kPa identifies treatment candidates 2, 4
- Liver biopsy is NOT required for treatment initiation per current guidelines 5
Dosing:
- 80 mg or 100 mg once daily orally 3
- Can be taken with or without food (food decreases Cmax by 33% but not clinically significant) 3
- No dose adjustment needed for mild hepatic impairment (Child-Pugh A) or mild-moderate renal impairment 3
Monitoring Protocol
Week 12 (Safety assessment only):
- Check liver enzymes to exclude hepatotoxicity signal
- Confirm absence of concomitant liver disease
- Do NOT assess efficacy at this timepoint - ALT changes at 12 weeks do not predict treatment response 2
Month 6 (Disease monitoring):
- Check aminotransferases
- Consider VCTE or MRI-PDFF for early response signals
- Absence of response at 6 months is insufficient to declare treatment failure 2
Month 12 and annually (Efficacy monitoring):
Continue treatment if:
- ALT improved ≥20% or normalized compared to baseline
- MRI-PDFF reduced by ≥30% (suggests likely histologic response)
- LSM stable or improved by VCTE or MRE 2
Discontinue treatment if:
- No MRI-PDFF response (if obtained at baseline)
- Worsening in ≥2 non-invasive tests
- LSM increased >30% on VCTE
- Drug intolerance (e.g., debilitating GI symptoms) 2
Safety Considerations
Common adverse reactions (>5% incidence):
- Diarrhea and nausea are most frequent
- Generally well tolerated with acceptable safety profile 1
Laboratory monitoring:
- Decreased free T4 (FT4) observed at 4 weeks - this is expected pharmacodynamic effect 3
- Increased sex hormone binding globulin (SHBG) - clinical significance unknown 3
- No clinically relevant QT prolongation 3
Important Caveats
Data limitations:
- Long-term sustainability of histological benefits unknown
- Impact on liver-related clinical outcomes (cirrhosis progression, hepatocellular carcinoma, liver-related mortality) not yet established
- Individual prediction of response remains unclear 1
Combination therapy:
- GLP-1 receptor agonists (semaglutide, tirzepatide) should be used for their approved indications (type 2 diabetes, obesity) as they improve cardiometabolic outcomes 1
- Real-world data shows frequent concomitant GLP-1 RA use with resmetirom, with treatment response appearing independent of weight-loss therapy 4
- Optimal sequencing and combination strategies remain under investigation 4, 6
Multidisciplinary approach essential: